Korean Celltrion Signs Letter Of Intent With U.S. CDC To Develop Rabies Agents

SEOUL - South Korean biopharmaceutical manufacturing company Celltrion signed a letter of intent Jan. 29 with the U.S. Centers for Disease Control to cooperate in the development and production of antibody drugs to fight rabies, a company official said Thursday